Producing Monoclonal Antibody Patents (Class 435/70.21)
-
Patent number: 7138241Abstract: The present invention provides for a method of selecting an antibody against a target substance to be measured, which comprises selecting the antibody against the target substance by antigen-antibody reaction in the presence of a substance interfering with the antigen-antibody reaction. That is, an antigen and a labeled antigen are reacted with the antibody in the presence of an interfering substance, such as an environment pollutant, and on the basis of the degree of reaction thereof, the antibody against the target substance, which is highly resistant to the interfering substance, is selected. Thereby, even if a test sample is contaminated with a substance interfering with antigen-antibody reaction, the antibody, which is highly resistant to the substance interfering with antigen-antibody reaction, is not influenced by the interfering substance and gives a correct value in the quantification.Type: GrantFiled: May 17, 2002Date of Patent: November 21, 2006Assignee: Japan Envirochemicals, Ltd.Inventors: Yasuhiro Goda, Ayako Kobayashi, Masato Hirobe
-
Patent number: 7138228Abstract: Post-translational O-sulfonation of a serine or threonine residue of proteins is detected, optionally comparatively, wherein the detected O-sulfonation is detected under a first physiological condition, and is compared with a control O-sulfonation detected under a second physiological condition, and a difference between the detected and control O-sulfonations indicates a difference between the first and second physiological conditions. Predetermined changes in physiological conditions are used to infer specific changes in O-sulfonation. Proteins are modified by introducing a predetermined change in O-sulfonation at a serine or threonine residue of the protein, and optionally, detecting a resultant change in O-sulfonation. These methods include introducing or increasing O-sulfonation, eliminating or reducing O-sulfonation; and derivatizing or substituting O-sulfonation.Type: GrantFiled: September 5, 2003Date of Patent: November 21, 2006Assignees: Regents of the University of California, Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Alma L. Burlingame, Katalin F. Medzihradszky, Zsuzsanna Darula, Eran Perlson, Michael Fainzilber, Robert J. Chalkley, Darren Tyson, Ralph A. Bradshaw
-
Patent number: 7135555Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: May 14, 2002Date of Patent: November 14, 2006Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 7135295Abstract: A protein comprising an antigen-binding portion formed by two cooperating peptide sequences of FIGS. 3A and 3B of the application. The protein may alternatively comprise an altered antigen-binding portion where at least one of the peptide sequences is an altered sequence, an altered sequence being a sequence of FIG. 3A or 3B in which one or more of an amino acid residue has been added, deleted or replaced by another amino acid residue. The altered antigen-binding portion retains substantially the same antigen-binding specificity as said antigen-binding portion. Also disclosed are apparatus, systems and methods for detecting small assayed molecules in a sample using the protein.Type: GrantFiled: January 25, 2000Date of Patent: November 14, 2006Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Yeda Research and Development Co. Ltd., Biosensor Applications Sweden ABInventors: Itamar Willner, Zelig Eshhar
-
Patent number: 7132280Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: September 3, 2002Date of Patent: November 7, 2006Assignee: Crucell Holland, B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 7132281Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: GrantFiled: February 10, 2004Date of Patent: November 7, 2006Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 7132511Abstract: The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.Type: GrantFiled: February 18, 2002Date of Patent: November 7, 2006Assignee: Merck Patent GmbHInventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
-
Patent number: 7118890Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: February 15, 2001Date of Patent: October 10, 2006Assignees: Yale University, Imperial Cancer Research Technology, Ltd.Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
-
Patent number: 7115715Abstract: Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).Type: GrantFiled: September 27, 2001Date of Patent: October 3, 2006Assignee: Institute of Virology Slovak Academy of SciencesInventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
-
Patent number: 7109309Abstract: It is intended to provide an antibody specific to HbA1c, antibody-producing cells capable of supplying the antibody in a stable state in the future, and a method of constructing the antibody-producing cells without any probability factors, and a method which comprises fusing mouse spleen cells, which have been sensitized with an immunogen composed of a compound containing the following structural formula (I) and a binding protein, with a myeloma-origin cell line, obtaining monoclonal antibody-producing cells by cloning, and then purifying and acquiring the monoclonal antibody produced by these cells into the culture supernatantType: GrantFiled: July 13, 2001Date of Patent: September 19, 2006Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Nobuyuki Shigetoh, Hiroshi Nakayama, Keiko Yugawa, Fumihisa Kitawaki
-
Patent number: 7109003Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: GrantFiled: July 1, 2003Date of Patent: September 19, 2006Assignees: Abgenix, Inc., Pfizer Inc.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 7105643Abstract: A monoclonal antibody, and a cell line capable of producing the same, has been produced with the ability to detect the primary metabolites generated from the pyrolysis of smokeable, or “crack”, cocaine. This monoclonal antibody, while being highly specific for anhydroecgonine methyl ester (AEME) and ecgonidine (ECD), does not cross-react at a significant level with the primary cocaine metabolites of powdered or injected cocaine. Also, crack cocaine conjugates capable of evoking an immune response in animals have been produced.Type: GrantFiled: July 30, 2003Date of Patent: September 12, 2006Assignee: The United States of America as represented by the Attorney General of the Dept. of JusticeInventor: Natalie T. Lu
-
Patent number: 7087396Abstract: A method for determining a soluble human ST2 in a sample conveniently at a high sensitivity and an assay kit are provided. By an immunological method comprising a step for bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2, a step for labelling a first reaction product generated in the previous step by reacting said first reaction product with a second anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from the site on ST2 where said first anti-human ST2 antibody binds and which is labelled with a label, and a step for determining the amount of the label on said first reaction product which has been labelled, a soluble human ST2 in a sample is determined. In addition, a recombinant ST2 is employed as a standard to prepare a calibration curve, based on which the ST2 in a sample is quantified.Type: GrantFiled: September 16, 2002Date of Patent: August 8, 2006Assignees: Medical Biological Laboratories Co., Ltd.Inventors: Shin-ichi Tominaga, Takao Arai, Kenji Kuroiwa, Katsuhisa Oshikawa
-
Patent number: 7087727Abstract: The invention includes novel human periostin polypeptides and DNAs encoding them. Also embraced by the invention are human periostin specific antibodies, diagnostic assays for metastasis of breast cancer to bone, and preeclempsia.Type: GrantFiled: August 13, 2002Date of Patent: August 8, 2006Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Lan Bo Chen, Meiru Dai, Hidefumi Sasaki, Daniel Auclair
-
Patent number: 7074903Abstract: Monocolonal antibodies having a higher reactivity with tartrate-resistant acid phosphatase 5b (TRACP 5b) than tartrate-resistant acid phosphatase 5a (TRACP 5a) and having a higher specificity to TRACP 5b can be obtained by cell fusion using as antigens TRACP 5b purified from human osteoclasts. By using the monoclonal antibody, TRACP 5b in a sample can be detected specifically with a high sensitivity.Type: GrantFiled: April 29, 2003Date of Patent: July 11, 2006Assignee: Nitto Boseki Co., Ltd.Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Kumiko Sasagawa, Katsuhiro Katayama
-
Patent number: 7070960Abstract: A method of determining the optimal level of product expression and cell growth of animal cell culture is described. The method generally comprises culturing cells under conditions of solute stress, that is, under conditions whereby optimal cell growth or growth rate is decreased yet levels of product expression are increased. In a preferred embodiment of the invention is described a method of increasing the yield of monoclonal antibodies comprising culturing hybridoma cells in an environment of solute stress. One approach to the creation of such an environment is the addition of inorganic salts, organic polyols, or metabolic products to the culture medium. One- to three-fold increases in antibody yield have been obtained by these methods.Type: GrantFiled: May 9, 2005Date of Patent: July 4, 2006Assignee: Chiron CorporationInventors: Brian Maiorella, Duane Inlow, William Howarth
-
Patent number: 7071311Abstract: The present invention relates to antibodies, antibody conjugates, and compositions thereof, methods of antibody synthesis, and applications of antibodies useful for detecting the presence of nucleic acid molecules in vivo, such as in a clinical setting. The antibodies of the invention are also useful as screening agents which allow the selection of candidate therapeutic molecules for optimum bioavailability and/or activity, and as delivery agents for cell and tissue specific delivery of nucleic acid molecules.Type: GrantFiled: February 12, 2003Date of Patent: July 4, 2006Assignee: Sirna Therapeutics, Inc.Inventors: Susan Radka, Leonid Beigelman, Haeberli Peter
-
Patent number: 7067268Abstract: The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand. The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity.Type: GrantFiled: May 20, 1999Date of Patent: June 27, 2006Assignee: Takeda Chemical Industries, Ltd.Inventors: Hirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
-
Patent number: 7056702Abstract: The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.Type: GrantFiled: December 16, 2002Date of Patent: June 6, 2006Inventors: Julie M. Villanueva, Stephen Quirk
-
Patent number: 7045605Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: May 30, 2002Date of Patent: May 16, 2006Assignee: Cornell Research Foundation, Inc.Inventors: Neil Bander, Francis J. Carr, Anita Hamilton
-
Patent number: 7041293Abstract: The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.Type: GrantFiled: June 23, 1998Date of Patent: May 9, 2006Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
-
Patent number: 7038021Abstract: The object of present invention is to provide an immunoassay for dioxins which can rapidly and simply afford measured values having a good correlation with analytical values of dioxins by the official method (GC/MS method). The above object is achieved by using the monoclonal antibody of the present invention having not only a reactivity with the indicator isomer among 17 kinds of PCDDs and PCDFs each having a predetermined WHO-TEF value, but also a high cross-reactivity with several kinds of dioxin isomers having five or six chlorine atoms which contribute largely to a TEQ value, and also having a stable reactivity with the antigens in a measuring solvent.Type: GrantFiled: July 7, 2004Date of Patent: May 2, 2006Assignee: Kyoto Electronics Manufacturing Co., Ltd.Inventors: Yoko Takagi, Kazuyuki Sawadaishi, Chiwa Kataoka
-
Patent number: 7033774Abstract: Polyclonal antibodies can be produced that reacts with recombinant EPO and its degradation products but not with native EPO. This antibody precipitation can be used to identify those glycopeptides that are uniquely reactive. These glycopeptides can be produced on preparative scale and used in the production of monoclonal antibodies which are screened against the original EPO and glycopeptides to select antibodies reactive to the specific glycopeptides an recombinant EPO but not to native human EPO. The monoclonal antibodies so selected are incorporated in a conventional ELISA and used to monitor urine and other bodily samples taken from athletes, either human or animal, and patients for presence and level of recombinant peptides or proteins. Alternatively, the polyclonal antibody can be used directly to produce ELISA tests.Type: GrantFiled: June 3, 2003Date of Patent: April 25, 2006Assignee: Glycozyme, Inc.Inventor: Allen K. Murray
-
Patent number: 7026140Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.Type: GrantFiled: September 2, 2004Date of Patent: April 11, 2006Assignee: Human Genome Sciences, Inc.Inventors: Peter L. Hudson, Wei Wu He, Steven M. Ruben
-
Patent number: 7018809Abstract: Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab? and F(ab?)2 antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.Type: GrantFiled: September 18, 1992Date of Patent: March 28, 2006Assignee: Genentech, Inc.Inventor: Paul J. Carter
-
Patent number: 7009040Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: January 21, 2003Date of Patent: March 7, 2006Assignee: Arius Research, Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Patent number: 7005503Abstract: Compositions are provided that comprise antibody against coreceptors for human immunodeficiency virus such as CCR5 and CXCR4. In particular, monoclonal human antibodies against human CCR5 are provided that bind to CCR5 with high affinity and are capable of inhibiting HIV infection at low concentrations. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, for screening drugs, and for diagnosing diseases or conditions associated with interactions with HIV coreceptors.Type: GrantFiled: February 8, 2002Date of Patent: February 28, 2006Assignee: Genetastix CorporationInventors: Shaobing Hua, Michelle H. Pauling, Li Zhu
-
Patent number: 6992177Abstract: Analogs of saquinavir functionalized at the quinoline portion of the molecule are described. These include pyridyl analogs (replacing the quinoline ring) with a functional handle out of the ring allowing for elaboration with linkers terminated by a functional group such as an activated ester which are useful for attaching the molecule to other entities such as proteins, polysaccharides, and the like. Analogs of saquinavir derivatized out of the quinoline ring are also described.Type: GrantFiled: December 10, 2004Date of Patent: January 31, 2006Assignee: Roche Diagnostics Operations, Inc.Inventors: Raymond A. Hui, Gerald F. Sigler, Richard T. Root, Wei Yuan
-
Patent number: 6967081Abstract: This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person.Type: GrantFiled: March 20, 2000Date of Patent: November 22, 2005Inventors: Sanna-Maria Käkönen, Heikki Luukinen, Kim Pettersson, Timo Lövgren, H. Kalervo Väänänen
-
Patent number: 6964854Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.Type: GrantFiled: July 13, 2000Date of Patent: November 15, 2005Assignee: Science & Technology CorporationInventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
-
Patent number: 6965018Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: June 6, 2001Date of Patent: November 15, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Glen E Mikesell, Han Chang, Robert J. Peach
-
Patent number: 6955717Abstract: The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.Type: GrantFiled: April 29, 2002Date of Patent: October 18, 2005Assignees: Medimmune Inc., Bowie State UniversityInventors: Leslie S. Johnson, Bradford Braden
-
Patent number: 6951645Abstract: A “cocktail” combination of two monoclonal antibodies respectively acting on different sites of the platelet GPIIb-IIIa complex has been disclosed. This “cocktail” combination can completely block receptor function of the GPIIb-IIIa complex, inhibit platelet aggregation and thereby efficiently inhibit thrombosis.Type: GrantFiled: July 17, 2003Date of Patent: October 4, 2005Inventors: Changgeng Ruan, George Qingwei Ye
-
Patent number: 6946255Abstract: The invention provides monoclonal antibodies, which specifically react with a Fas ligand, or active fragments thereof, a production process of the monoclonal antibodies, which specifically react with a Fas ligand, hybridomas separately producing a monoclonal antibody, which specifically reacts with a Fas ligand present on a cell surface, a method of detecting a Fas ligand in a solution, and a kit for use in detecting a Fas ligand, comprising plurality of monoclonal antibodies against Fas ligand in combination.Type: GrantFiled: March 21, 1996Date of Patent: September 20, 2005Assignee: Ko OkumuraInventors: Nobuhiko Kayagaki, Hideo Yagita, Ko Okumura, Motomi Nakata
-
Patent number: 6929924Abstract: The present invention relates to a specific C-peptide assay method which can eliminate all interference due to proinsulin and its intermediates, in particular des-31,32-proinsulin and/or des-64,65-proinsulin. It also relates to antibodies for carrying out this assay.Type: GrantFiled: March 4, 2004Date of Patent: August 16, 2005Assignee: Pasteur Sanofi DiagnosticsInventors: Majida Bouanani, Nadia Kamal, Catherine Christianne Marie Larue, Bernard Christian Pau, Elisabeth Siohan
-
Patent number: 6927035Abstract: A monoclonal antibody which reacts strongly with uracil and thymine but scarcely with N-carbamyl-?-alanine; a hybridoma producing this monoclonal antibody; a method of immunochemically assaying uracil or thymine characterized by using the above-described monoclonal antibody; and diagnostics for DPD deficiency containing the above monoclonal antibody. Because of high sensitivity and specific reaction with uracil and thymine, the above-described monoclonal antibody enables convenient, quick, and selective assaying of uracil and thymine in a sample. The antibody is useful in screening patients with DPD deficient cancer with contraindication to the administration of pyrimidine fluoride-based antitumor agents.Type: GrantFiled: October 18, 2000Date of Patent: August 9, 2005Assignees: Taiho Pharmaceutical Co., LTD, Biomedical Research Group Inc.Inventor: Gen-ichiro Soma
-
Patent number: 6919183Abstract: A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.Type: GrantFiled: January 16, 2002Date of Patent: July 19, 2005Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Neil Stahl, Gang Chen, George D. Yancopoulos
-
Patent number: 6916628Abstract: The present invention provides a method for qualitative determination of low molecular weight soluble CD14 proteins separately. The present invention also provides antibodies specific to high molecular weight soluble CD14 proteins. Further, the present invention provides a measurement method for specifically determining the quality or quantity of high molecular weight soluble CD14 proteins using the antibodies with high sensitivity, simplicity and specificity.Type: GrantFiled: September 18, 2000Date of Patent: July 12, 2005Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Shouji Furusako, Kamon Shirakawa
-
Patent number: 6913756Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.Type: GrantFiled: April 29, 1998Date of Patent: July 5, 2005Assignee: The UAB Research FoundationInventor: John F. Kearney
-
Patent number: 6913894Abstract: Monoclonal antibodies which bind specifically to the extracellular domain of the SIRP cell surface glycoproteins, and which, in some cases, block the interaction of SIRP with the surface molecule CD47, are described.Type: GrantFiled: May 29, 2002Date of Patent: July 5, 2005Assignee: Eberhard-Karls-Universitat Tubingen UniversitatsklinikumInventors: Hans-Jörg Bühring, Axel Ullrich, Zhengjun Chen, Charles Cant
-
Patent number: 6905847Abstract: A method of determining the optimal level of product expression and cell growth of animal cell culture is described. The method generally comprises culturing cells under conditions of solute stress, that is, under conditions whereby optimal cell growth or growth rate is decreased yet levels of product expression are increased. In a preferred embodiment of the invention is described a method of increasing the yield of monoclonal antibodies comprising culturing hybridoma cells in an environment of solute stress. One approach to the creation of such an environment is the addition of inorganic salts, organic polyols, or metabolic products to the culture medium. One-to three-fold increases in antibody yield have been obtained by these methods.Type: GrantFiled: May 30, 2001Date of Patent: June 14, 2005Assignee: Chiron CorporationInventors: Brian Maiorella, Duane Inlow, William Howarth
-
Patent number: 6890721Abstract: Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilize such ICE LAP-6 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.Type: GrantFiled: September 24, 2001Date of Patent: May 10, 2005Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation, The Regents of the University of MichiganInventors: Vishva M. Dixit, Wei-Wu He, Kristine K. Kikly, Steven M. Ruben
-
Patent number: 6875580Abstract: The invention provides immunological reagents (antibodies) capable of binding to plasmacytoid dendritic cells (pDC), to cell lines which express such antibodies and to a process for identifying and purifying plasmacytoid dendriticcells from tissues containing pDC using such antibodies.Type: GrantFiled: January 26, 2004Date of Patent: April 5, 2005Assignee: Schering CorporationInventors: Carine Paturel, Giorgio Trinchieri, Jean-Jacques Pin
-
Patent number: 6863892Abstract: A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.Type: GrantFiled: August 22, 2001Date of Patent: March 8, 2005Assignee: Agensys, Inc.Inventors: Mary Faris, Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Elana Levin, Pia Challita-Eid, Aya Jakobovits
-
Patent number: 6855508Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: August 5, 2002Date of Patent: February 15, 2005Assignee: Genentech, Inc.Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 6849720Abstract: There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.Type: GrantFiled: March 8, 2001Date of Patent: February 1, 2005Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nachum Yonah, Dany Suissa, Ilana Belzer, Francesco Antonetti, Moshe Smolarsky, Michel Dreano
-
Patent number: 6838250Abstract: The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.Type: GrantFiled: March 29, 2001Date of Patent: January 4, 2005Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Edward R. Scalice, John L. Daiss
-
Patent number: 6838264Abstract: Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and/or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH.Type: GrantFiled: December 5, 2000Date of Patent: January 4, 2005Assignee: Immutopics, Inc.Inventors: Richard J. Zahradnik, Jeffrey R. Lavigne
-
Publication number: 20040265976Abstract: The invention relates to novel CD1a-presented antigens. These antigens can be used as antigens, adjuvants or as immunomodulatory agents in a variety of diagnostic, therapeutic and prophylactic applications.Type: ApplicationFiled: April 19, 2004Publication date: December 30, 2004Applicants: The Brigham and Women's Hospital, Inc., Trustees of Boston UniversityInventors: D. Branch Moody, David C. Young, Catherine E. Costello
-
Publication number: 20040265329Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: April 22, 2004Publication date: December 30, 2004Applicant: Willmar Poultry Company, Inc.Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig